Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid
Stock Information for Akari Therapeutics Plc
Loading
Please wait while we load your information from QuoteMedia.